{"DataElement":{"publicId":"2682055","version":"1","preferredName":"Neoadjuvant Therapy Follow-up Trastuzumab Administration End Date","preferredDefinition":"the end date trastuzumab, a humanized recombinant monoclonal antibody directed against the HER2- receptor protein, was administered as treatment during follow-up to neoadjuvant therapy, treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents.","longName":"NEO_J_FU_TRA_AD_E_DT","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2682017","version":"1","preferredName":"Neoadjuvant Therapy Follow-up Trastuzumab Administration","preferredDefinition":"information related to the administration of trastuzumab, a humanized recombinant monoclonal antibody directed against the HER2- receptor protein,  treatment during follow-up to neoadjuvant therapy, treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents.","longName":"FU_NEOADJ_TRAST_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2681997","version":"1","preferredName":"Neoadjuvant Therapy Follow-up","preferredDefinition":"Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains.:The process by which information about the health status of an individual is obtained after a study has officially closed.","longName":"C15665:C16033","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Follow-Up","conceptCode":"C16033","definition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A1A6AAA-510A-627D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-14","modifiedBy":"ONEDATA","dateModified":"2007-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2682015","version":"1","preferredName":"Trastuzumab Administration","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI):The act of administration.","longName":"C1647:C25409","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab","conceptCode":"C1647","definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A1BD6D7-9EE0-3E03-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-14","modifiedBy":"ONEDATA","dateModified":"2007-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A1BD6D7-9EF1-3E03-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2188674","version":"1","preferredName":"End Date","preferredDefinition":"The date on which an observation or an event ended.","longName":"END_DT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"mm/dd/yy","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184285","version":"1","preferredName":"Date","preferredDefinition":"A particular day specified as the time something has, or will, happen.","longName":"Date","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1B1A-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E53ADB93-5DF7-315A-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-29","modifiedBy":"KNABLEJ","dateModified":"2017-08-23","changeDescription":"8/23/17 jk transferred context, cap first letter in def, and added CSI, registration status per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Treatment end date","type":"Preferred Question Text","description":"Treatment end date","url":null,"context":"CTEP"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3A1C810E-081F-5769-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-14","modifiedBy":"CAMPBELB","dateModified":"2008-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}